Insurance vs. Cash-Pay: Understanding GLP-1 Access Routes

Why coverage varies so much

The single biggest factor is whether the prescription is on-label or off-label for your situation. A medication's FDA-approved label names the conditions and populations it was authorized for. Prescribing outside those bounds is legal and routine, but insurers generally build coverage rules around the label — so the same drug may be readily covered for one diagnosis and flatly excluded for another.

It's not a glitch — it's the predictable result of how U.S. drug coverage is structured.

Layered on top of that, "insurance" isn't one policy. Coverage decisions are made by whoever bears the cost:

• Employer-sponsored plans often decide independently whether to include weight-management drugs at all. Large self-funded employers can add or drop that category, sometimes at short notice.
• The formulary — your plan's list of covered drugs and their tiers — sets your share of the cost. A drug can be covered but placed on a specialty tier with a much larger copay or coinsurance.
• Pharmacy benefit managers negotiate on the plan's behalf, and their rebate arrangements shape which product in a class is preferred.
• Public programs follow their own statutes. Medicare's drug benefit has long operated under a statutory exclusion for drugs used for weight loss, with coverage possible where a product carries another approved indication; Medicaid rules are set state by state.

The practical implication: nothing you read online about "whether it's covered" is authoritative for you. Only your plan's own documents are.

What prior authorization typically involves

Prior authorization is a plan's requirement that your prescriber justify the prescription before it will pay. Criteria differ, but requests tend to ask for the same categories of evidence:

• A qualifying diagnosis code. The ICD-10 code your clinician submits has to line up with the indication your plan covers. This is often where an approval succeeds or fails.
• Documented clinical criteria. Depending on the indication: recorded measurements such as BMI, lab values such as A1c, and related conditions — sleep apnea, hypertension, dyslipidemia, cardiovascular disease — written in your chart, not just mentioned in conversation.
• Step therapy. Many plans require you to have tried lower-cost alternatives first, with that history documented.
• Lifestyle-intervention documentation. Some plans ask for evidence of participation in a diet, exercise, or behavioral program over a defined period.
• Reauthorization. Approvals are usually time-limited, and renewal often depends on documented follow-up and continued eligibility.

If a request is denied, plans must provide a reason and an appeals process — typically internal review followed by independent external review. A denial is a stage, not necessarily the end, but pursuing it takes time from both you and your prescriber's office.

The cash-pay and telehealth route

Cash-pay means paying without billing insurance. People generally encounter a few models: a retail or discount-program price at a pharmacy, a manufacturer's self-pay channel where one exists, or a telehealth service that bundles a clinical consultation with medication fulfillment for a recurring fee.

Telehealth platforms in this space connect patients with clinicians licensed in the patient's state, who evaluate eligibility remotely and prescribe if they judge it appropriate; a partnered pharmacy then dispenses. Clinical depth and follow-up vary considerably between services, and a platform being willing to prescribe is not itself an assessment of whether you should take something.

One area where the rules have shifted is compounded versions. Under U.S. law, compounding pharmacies may prepare a copy of an FDA-approved drug only in limited circumstances — notably while that drug is on the FDA's official shortage list. During the shortages of 2023 and 2024 that exception permitted a large compounded GLP-1 market. The FDA subsequently declared those shortages resolved — tirzepatide in late 2024, semaglutide in early 2025 — narrowing what compounders may lawfully produce, and enforcement and litigation followed. Compounded preparations are not FDA-approved products and are not reviewed for safety, efficacy, or manufacturing quality in the same way. If a service offers one, ask what exactly you're being sold, which pharmacy prepares it, and on what legal basis. This area keeps changing: verify the current position with the FDA and your state pharmacy board rather than relying on any article, including this one.

What cash-pay pricing actually consists of

Cash-pay prices in this category span a very wide range — wide enough that two services described in the same article can differ several-fold. That range is mostly explained by what is being sold rather than by one provider being a better deal than another. The tiers you'll encounter, roughly from most to least expensive:

• Brand-name product at list or near-list price through a pharmacy, without insurance and without a discount program. This is the top of the range and the reason cash-pay has a reputation for being unaffordable.
• Brand-name product through a manufacturer's own self-pay channel, where one exists for that product. These channels typically cover the FDA-approved product at a set monthly price, usually with conditions attached — specific doses, direct fulfilment, no insurance billing.
• A telehealth subscription bundling consultation and brand-name medication, priced monthly. The medication is usually the dominant component of the price.
• A telehealth subscription bundling consultation and a compounded preparation. This tier is materially cheaper, and the reason is that a compounded preparation is not the FDA-approved product — see the section above on why that distinction is both legal and clinical, not just financial.
• Consultation-only services, where you pay a smaller fee for the clinical visit and prescription, then buy the medication separately at whatever your pharmacy charges. Cheapest headline number, but it isn't the total.

We deliberately don't publish dollar figures. Prices in this category have changed repeatedly and substantially — manufacturer self-pay channels, shortage status, and platform pricing have all moved within the space of months — and a stale number in an article is worse than no number, because people plan around it. Get current pricing in writing from the provider, and price the tier you'd actually be on at the dose you'd actually be taking.

Questions to ask any telehealth provider before you sign up

Services in this space vary widely in clinical depth, and the marketing rarely reveals which kind you're dealing with. These questions do. Ask them before you pay, and ask for the answers in writing.

• Exactly what product will I be dispensed? Is it the FDA-approved brand-name product, a generic where one exists, or a compounded preparation? Get the answer as a specific product name, not a molecule name — the distinction is easy to blur in marketing copy.
• If it's compounded, which pharmacy prepares it, where is it licensed, and on what legal basis is it being compounded? A provider that won't name the pharmacy has answered a different question than the one you asked.
• Who is the prescribing clinician, what is their license type, and are they licensed in my state? A named, verifiable clinician licensed where you live is the baseline, not a bonus.
• Is there a real clinical evaluation, and does it include my history, current medications, and labs? Ask specifically whether anything is ruled out — a service that appears to approve everyone is telling you something about its evaluation.
• What follow-up is included? How often will I be seen, by whom, and what happens between visits if something goes wrong? Is there a way to reach a clinician — not a chatbot or a support queue — about a side effect?
• What's included in the price, and what isn't? Consultation, follow-ups, dose changes, needles and supplies, shipping, labs.
• What are the billing terms? Is this a subscription, does it auto-renew, is there a minimum commitment, how do I cancel, and what is and isn't refundable if I stop or can't tolerate the medication?
• Will you coordinate with my regular clinician? Will records be shared, and who holds responsibility for monitoring? Fragmented care is one of the practical risks of this route.
• What happens if supply is interrupted or my dose isn't available?
• How is my health data handled? Is the service operating under HIPAA, what is shared with third parties, and what happens to your data if you cancel?

A legitimate provider will answer all of these plainly. Evasiveness on any of them — particularly on what product you're being sold and who is prescribing it — is information in itself.

What to watch out for

Two categories of risk in this market deserve to be named directly.

Compounding pharmacy quality

Compounded preparations are not FDA-approved products. They are not reviewed for safety, efficacy, or manufacturing consistency the way an approved product is, and quality depends heavily on the individual pharmacy — its licensing, its inspection history, and whether it is a state-licensed compounder or a larger outsourcing facility registered under a different section of federal law. The FDA has publicly reported adverse events associated with compounded GLP-1 products, including dosing errors where patients drew up the wrong volume from multi-dose vials that lacked the pre-set doses of a manufactured pen. If you are considering a compounded preparation, that is a conversation to have with your own clinician, with the pharmacy named.

Gray-market and "research" suppliers

There is an online market selling GLP-1 peptides directly to consumers — commonly labelled "for research use only," "not for human consumption," or sold as raw powder to be reconstituted at home. Marketing sometimes uses the names of investigational, unapproved molecules. These products sit entirely outside the pharmacy system: no prescription, no licensed pharmacist, no verified contents, dose, sterility, or purity, and no recourse if something goes wrong. Regulators have repeatedly warned about counterfeit and unapproved injectable products in this category, including counterfeit pens entering legitimate-looking supply channels.

Other things worth treating as warning signs on any route: pressure to buy immediately or a countdown timer on a medical decision; guaranteed results or before-and-after imagery; no named clinician; no mechanism to report a side effect; a refusal to put the product name in writing; and prices far below every other option, which usually indicates you are being sold something different from what you think.

HSA and FSA basics

Health Savings Accounts and Flexible Spending Accounts let you pay certain health expenses with pre-tax dollars, effectively discounting them by your marginal tax rate. As a general rule, medications prescribed for a diagnosed medical condition are qualifying expenses; purchases for general health or cosmetic purposes are not. Some administrators request a Letter of Medical Necessity for weight-related treatment, and telehealth consultation fees may or may not qualify depending on how the service bills them.

Rules are set by the IRS, interpreted by your plan administrator, and subject to change. Confirm eligibility before assuming a purchase will be reimbursed, and keep receipts — substantiation requests are common.

A framework for comparing cost

Comparing routes on the headline price is the most common mistake, because the headline rarely covers the same things. We don't publish dollar figures — they change constantly and vary by plan, pharmacy, and location — but you can build an apples-to-apples comparison by pricing the same variables for each route:

• Cost per month at your maintenance dose, not the starting dose — titration means early months may not reflect ongoing cost.
• What's bundled. Consultation, follow-up visits, dose changes, supplies, shipping — included, or billed separately?
• Deductible position. Under insurance, cost early in the plan year can differ sharply from cost later, and out-of-pocket maximums cap only covered services.
• Copay vs coinsurance. A flat copay is predictable; coinsurance is a percentage of a price you don't control.
• Manufacturer savings programs — eligibility restrictions, expiry dates, and whether any amount counts toward your deductible.
• Continuity risk. What happens if the plan drops the category at renewal, an authorization lapses, or a platform changes pricing or supply?
• Monitoring costs. Labs and follow-up are part of treatment, and may be covered on one route but not the other.
• Total cost over twelve months, since this is generally not a short course of treatment.

Deciding between them

Neither route is inherently better. Insurance can substantially reduce cost when the prescription is on-label and criteria are met, at the price of paperwork, delay, and the risk of denial or non-renewal. Cash-pay trades that for predictability and speed, at a price you bear in full and with a wider quality range among providers. Which fits depends on your diagnosis, your plan's actual policy language, and how much variability you can absorb — and the clinical question comes first either way. Our list of questions to ask your doctor covers what to establish before cost enters the picture, and the plain-English overview explains what this class of medication actually does.